ArticleBMJ (Clinical research ed.)2024
Use of progestogens and the risk of intracranial meningioma: national case-control study.
Article in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.The Prostate · 2026Pooled it
- Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology.Neurology · 2026Article
- Exogenous Hormones and Their Clinical Implications for the Development and Growth of Meningioma Tumours.Journal of clinical medicine · 2026Review
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Contraceptive Progestogens and Incident Meningioma.JAMA network open · 2026Article
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- A Systematic Review and Meta-Analysis of the Association Between Depot Medroxyprogesterone Acetate and Cerebral Meningioma.Cancers · 2026Review
- Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.Circulation · 2026Article
- Medical Treatment for Endometriosis: One Size Does Not Fit All.Journal of clinical medicine · 2026Review
- Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Causal Pathways Linking Gut Microbiota, Serum Metabolites, and Meningioma Risk: A Mendelian Randomization Analysis.Brain and behavior · 2026Article
- Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.Neuro-oncology · 2026Article
- Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users.Journal of neuro-oncology · 2026Article
- MRI and Meningioma Research: Hotspots and Trends via Bibliometric AnalysisCurrent medical imaging · 2026Article
- PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study.The Lancet regional health. Europe · 2025Article
- Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US.JAMA neurology · 2025Article
- Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies.The Lancet regional health. Europe · 2025Article
- Tumor behavior disparities in all-cause and cause-specific mortality among patients with central nervous system tumors.Scientific reports · 2025Article
- The Association Between Medroxyprogesterone Acetate Exposure and Cerebral Meningioma Among a Medicaid Population.Epidemiologia (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the risk of intracranial meningioma associated with the use of selected progestogens.
designNational case-control study.
settingFrench National Health Data System (ie,
participantsOf 108 366 women overall, 18 061 women living in France who had intracranial surgery for meningioma between 1 January 2009 and 31 December 2018 (restricted inclusion periods for intrauterine systems) were deemed to be in the case group. Each case was matched to five controls for year of birth and area of residence (90 305 controls).
main outcome measuresSelected progestogens were used: progesterone, hydroxyprogesterone, dydrogesterone, medrogestone, medroxyprogesterone acetate, promegestone, dienogest, and intrauterine levonorgestrel. For each progestogen, use was defined by at least one dispensation within the year before the index date (within three years for 13.5 mg levonorgestrel intrauterine systems and five years for 52 mg). Conditional logistic regression was used to calculate odds ratio for each progestogen meningioma association.
resultsMean age was 57.6 years (standard deviation 12.8). Analyses showed excess risk of meningioma with use of medrogestone (42 exposed cases/18 061 cases (0.2%)
conclusionsProlonged use of medrogestone, medroxyprogesterone acetate, and promegestone was found to increase the risk of intracranial meningioma. The increased risk associated with the use of injectable medroxyprogesterone acetate, a widely used contraceptive, and the safety of levonorgestrel intrauterine systems are important new findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.